NHS failed to hear concerns of family in death of five-year-old boy
Yusuf, who had asthma, died after the infection spread to his lungs.He was first seen by a GP on 15 November 2022 and prescribed antibiotics. He was taken to Rotherham General Hospital's emergency department, but was discharged with more medication.Yusuf's family said they were told they were "no beds and not enough doctors" and their son could not be admitted.On November 18, he was taken to Sheffield Children's Hospital and three days later he was admitted to intensive care.On 23 November Yusuf died after multiple organ failure and several cardiac arrests as a result of the infection.
'Reduced trust'
A report into Yusuf's case in October 2023, by independent consultants and published by NHS South Yorkshire, found his care was appropriate and "an admission was not clinically required", but this was rejected by his family.The new report, led by the former general secretary of the Royal College of Nursing, Peter Carter, found "a reliance on clinical metrics over caregiver insight caused distress for the family".It said: "This led to a lack of shared decision-making and there was limited evidence of collaborative discussions with Yusuf's family around clinical decisions, leading to a sense of exclusion and reduced trust in care plans."
Health Secretary Wes Streeting, who met Yusuf's family last year, said their concerns had "repeatedly not been addressed" by the NHS.He said: "There are no excuses for the tragic failings in the lead up to Yusuf's death and I know first hand how hard it has been for his family to live without the answers they deserve."It is now the responsibility of the NHS to implement the recommendations in this report so that the family can at least take small comfort in knowing that because of Yusuf, and thanks to Yusuf, children will be safer and better cared for in the future."The family has called on the NHS to learn lessons from Yusuf's death.His mother, Sonyia Ahmed, said: "The failings identified are truly shocking. Yusuf deserved better, every child does. "I will never stop speaking his name. I will never stop fighting for him. We demand accountability, we demand change. "This is why we want an inquest."
Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
6 minutes ago
- Daily Mail
Shower gel advert banned for depicting black skin as 'problematic' and white skin as 'superior' by advertising watchdog
A shower gel advert has been banned for depicting black skin as 'problematic' and white skin as 'superior', the advertising watchdog has said. The Advertising Standards Authority (ASA) banned the ad after investigating complaints that it perpetuated a 'negative and offensive racial stereotype'. The Sanex shower gel ad, broadcast in June, depicted a black woman with red scratch marks and another covered with a cracked clay-like material. Over this, a voiceover said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water.' Over scenes of a white woman the ad stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover adding: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, argued the depiction of diverse models in the ad was shown in a 'before and after' scenario to demonstrate their product was suitable for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for television broadcast, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. However the ASA said the use of different skin colours created a juxtaposition of black skin shown as itchy and dry in the 'before' scenes, and white skin shown as smoother in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' Colgate-Palmolive was approached for comment.
The Independent
7 minutes ago
- The Independent
Major brand has advert banned for suggesting black skin is ‘problematic'
A Sanex shower gel television advertisement has been banned by the Advertising Standards Authority (ASA) for reinforcing an offensive racial stereotype. The watchdog ruled the ad, which suggested black skin was "problematic" and white skin "superior", must not air again. This followed two complaints that it perpetuated negative stereotypes about darker skin tones. The ad, seen in June, included a voiceover that said: 'To those who might scratch day and night. To those whose skin will feel dried out even by water,' alongside scenes of a black woman with red scratch marks and another covered with a cracked clay-like material. Alongside scenes of a white woman taking a shower with the product, the ad then stated: 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24 hour hydration feel.' The ad ended with on-screen text and the voiceover stating: 'Relief could be as simple as a shower.' Colgate-Palmolive, which owns the Sanex brand, said the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was shown in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity. On that basis, it believed the ad did not perpetuate negative racial stereotypes and was not likely to cause serious or widespread offence. Clearcast, which approves or rejects ads for broadcast on television, said the ad did not perpetuate negative racial stereotypes and instead demonstrated the product's inclusivity. The agency said one model with darker skin was depicted in a 'stylised and unrealistic way' to demonstrate dryness, but her skin tone was otherwise not a focal point. A second model, also with darker skin, was shown with itchy skin, but this was portrayed through scratching visibly healthy skin and the resulting marks, and was therefore more about sensation than any visible skin condition. The ASA said the use of different skin colours was a means of portraying a 'before and after' of the product's use, which created a juxtaposition of black skin shown as itchy, dry and cracked in the 'before' scenes, and white skin shown as smoother skin in the 'after' scenes. The watchdog said: 'The ad was therefore structured in such a way that it was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved. 'We considered that could be interpreted as suggesting that white skin was superior to black skin.' The ASA added: 'Although we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers, we considered that the ad was likely to reinforce the negative and offensive racial stereotype that black skin was problematic and that white skin was superior. 'We concluded that the ad included a racial stereotype and was therefore likely to cause serious offence.' It further told Colgate-Palmolive 'to ensure they avoided causing serious offence on the grounds of race'.
The Independent
7 minutes ago
- The Independent
Diabetes patients could be offered weight loss jabs sooner in major shake-up
People with type 2 diabetes in England could be offered treatments, including weight loss jabs, sooner in the biggest shake-up of care in a decade. New draft guidance from the National Institute for Health and Care Excellence (Nice) recommends a shift from a one-size-fits-all approach of starting everyone on the same medication to more personalised care that aims to prevent complications like heart failure and heart attacks. Newer type 2 diabetes drugs, known as SGLT-2 inhibitors, would be made a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as control blood sugar, Nice said. It is estimated that the change could save almost 22,000 lives once uptake reaches 90 per cent of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
